Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Bonsang Kitzis, H ^a,b   Sadacca, B ^a,b,c   Hamy Petit, A S ^a,b   Moarii, M ^d,e   Pinheiro, A ^a,b   Laurent, C ^a,b   Reyal, F ^a,b  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e INSERM U900   (France)

Author keywords

immune signature; molecular subtypes; prognosis; triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; JANUS KINASE 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; QUALITY CONTROL; SCORING SYSTEM; SIGNAL TRANSDUCTION; STROMA CELL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GENE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 85075090992     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1061176     Document Type: Article

References (69)

1. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Ggenom 2006; 7:96; PMID:16643655; http://dx.doi.org/10.1186/1471-2164-7-96
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98(19):10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098
3. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8):1160-7; PMID:19204204; http://dx.doi.org/10.1200/JCO.2008.18.1370
4. Hennessy BT, Gonzalez-Angulo A-M, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69(10):4116-24; PMID:19435916; http://dx.doi.org/10.1158/0008-5472.CAN-08-3441
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363(20):1938-8; PMID:21067385; http://dx.doi.org/10.1056/NEJMra1001389
6. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013; 19(23):6380-8; PMID:24298068; http://dx.doi.org/10.1158/1078-0432.CCR-13-0915
7. Von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31(29):3623-30; PMID:24002511; http://dx.doi.org/10.1200/JCO.2012.45.0940
8. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81; PMID:18250347; http://dx.doi.org/10.1200/JCO.2007.14.4147
9. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384(9938):164-72; PMID:24529560; http://dx.doi.org/10.1016/S0140-6736(13)62422-8
10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol J. A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7):2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
11. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Informat 2012; 11:147-56; PMID:22872785; http://dx.doi.org/10.4137/CIN.S9983
12. Sontrop HMJ, Moerland PD, van den Ham R, Reinders MJT, Verhaegh WFJ. A comprehensive sensitivity analysis of microarray breast cancer classification under feature variability. BMC Bioinformatics 2009; 10:389; PMID:19941644; http://dx.doi.org/10.1186/1471-2105-10-389
13. Abraham G, Kowalczyk A, Loi S, Haviv I, Zobel J. Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics 2010; 11:277; PMID:20500821; http://dx.doi.org/10.1186/1471-2105-11-277
14. Fröhlich H. Network based consensus gene signatures for biomarker discovery in breast cancer. PLoS One 2011; 6(10):e25364; PMID:22046239; http://dx.doi.org/10.1371/journal.pone.0025364
15. Cun Y, Fröhlich HF. Prognostic gene signatures for patient stratification in breast cancer: accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions. BMC bioinformatics 2012; 13:69; PMID:22548963; http://dx.doi.org/10.1186/1471-2105-13-69
16. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30(16):1996-2004; PMID:22508827; http://dx.doi.org/10.1200/JCO.2011.39.5624
17. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403):346-52; PMID:22522925; http://dx.doi.org/10.1038/nature10983.
18. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010; 28(28):4316-4323; PMID:20805453; http://dx.doi.org/10.1200/JCO.2009.27.2419
19. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011; 13(5):R97; PMID:21978456; http://dx.doi.org/10.1186/bcr3035
20. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treatment 2011; 126:407-420; PMID:20490655; http://dx.doi.org/10.1007/s10549-010-0897-9
21. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8(8):R157; PMID:17683518; http://dx.doi.org/10.1186/gb-2007-8-8-r157
22. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14(16):5158-65; PMID:18698033; http://dx.doi.org/10.1158/1078-0432.CCR-07-4756
23. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123(7):1-20; PMID:23778140; http://dx.doi.org/; http://dx.doi.org/10.1172/JCI67428
24. Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PloS One 2011; 6(12):e28403; PMID:22220191; http://dx.doi.org/10.1371/journal.pone.0028403
25. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2014; 21(7):1688-98; PMID:25208879; http://dx.doi.org/10.1158/1078-0432.CCR-14-0432.
26. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A et al. A pathway-based classification of human breast cancer. Proc Natal Acad Sci U S A 2010; 107:6994-9; PMID:20335537; http://dx.doi.org/10.1073/pnas.0912708107
27. Palmer C, Diehn M, Alizadeh AA, Brown PO. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006; 7:115; PMID:16704732; http://dx.doi.org/10.1186/1471-2164-7-115
28. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C et al. Stromal contribution to the colorectal cancer transcriptome. Nature Genet 2015; 47(4):312-9; PMID:25547594; http://dx.doi.org/10.1038/ng.3224
29. Schalper K A., Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased tils and better outcome in breast carcinomas. Clin Cancer Res 2014; 20:2773-82; PMID:24647569; http://dx.doi.org/10.1158/1078-0432.CCR-13-2702
30. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2015; 6(7):5449-64; PMID:25669979
31. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet Oncol 2010; 11(4):339-49; PMID:20181526; http://dx.doi.org/10.1016/S1470-2045(10)70008-5
32. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200(4):429-47; PMID:12845611; http://dx.doi.org/10.1002/path.1398
33. Lum DH, Matsen C, Welm AL, Welm BE. Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol 2012;Chapter 14(801):Unit 14.22; PMID:23258598; http://dx.doi.org/10.1002/0471141755.ph1422s59
34. Sanavia T, Aiolli F, Da San Martino G, Bisognin A, Di Camillo B. Improving biomarker list stability by integration of biological knowledge in the learning process. BMC Bioinformatics 2012; 13 Suppl 4(Suppl 4):S22; PMID:22536969; http://dx.doi.org/10.1186/1471-2105-13-S4-S22
35. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12(4):298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
36. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28(1):105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370
37. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14(5):518-27; PMID:18438415; http://dx.doi.org/10.1038/nm1764
38. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1(1):54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
39. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68(13):5405-13; PMID:18593943; http://dx.doi.org/10.1158/0008-5472.CAN-07-5206
40. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8(8):R157; PMID:17683518; http://dx.doi.org/10.1186/gb-2007-8-8-r157
41. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adélaïde J, Debono S, Houvenaeghel G, Maraninchi D, Viens P et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66(9):4636-44; PMID:16651414; http://dx.doi.org/10.1158/0008-5472.CAN-06-0031
42. Von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30(15):1796-804; PMID:22508812; http://dx.doi.org/10.1200/JCO.2011.38.8595
43. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71(14):4809-20; PMID:21646474; http://dx.doi.org/10.1158/0008-5472.CAN-11-0753
44. Denkert C, von Minckwitz G, Brase JC, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang D. Schmitt et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33(9):983-91; PMID:25534375; http://dx.doi.org/10.1200/JCO.2014.58.1967
45. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13(6):R126; PMID:22151962; http://dx.doi.org/10.1186/bcr3072
46. Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 2014; 13:228; PMID:25277734; http://dx.doi.org/10.1186/1476-4598-13-228
47. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 2015; 3(4):326-32; PMID:25527356; http://dx.doi.org/10.1158/2326-6066.CIR-14-0133
48. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 2013; 5(3):169-81; PMID:23634195; http://dx.doi.org/10.1177/1758834012475152
49. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006; 25(28):3994-4008; PMID:16491124; http://dx.doi.org/10.1038/sj.onc.1209415
50. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Inter J Clin Oncol 2008; 13(5):431-5; PMID:18946753; http://dx.doi.org/10.1007/s10147-008-0770-6
51. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012; 29(2):406-10; PMID:21264529; http://dx.doi.org/10.1007/s12032-011-9832-0
52. Luo X, Shi Y-X, Li Z-M, Jiang W-Q. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 2010; 29(6):585-90; PMID:20507730; http://dx.doi.org/10.5732/cjc.009.10673
53. Rakha E A, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109(1):25-32; PMID:17146782; http://dx.doi.org/10.1002/cncr.22381
54. McNamara KM, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci 2013; 104(5):639-46; PMID:23373898; http://dx.doi.org/10.1111/cas.12121
55. Peters A A, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69(15):6131-40; PMID:19638585; http://dx.doi.org/10.1158/0008-5472.CAN-09-0452
56. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21(14):2245-52; PMID:11948407; http://dx.doi.org/10.1038/sj/onc/1205291.
57. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25(1):9-34; PMID:16680569; http://dx.doi.org/10.1007/s10555-006-7886-9
58. Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer2007; 96(6):903-11; PMID:17342087; http://dx.doi.org/10.1038/sj.bjc.6603666
59. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Annals Oncol 2008; 19(9):1566-72; PMID:18503039; http://dx.doi.org/10.1093/annonc/mdn180
60. Figueira RCS, Gomes LR, Neto JS, Silva FC, Silva IDCG, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9:20; PMID:19144199; http://dx.doi.org/10.1186/1471-2407-9-20
61. González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Human Pathol 2009; 40(9):1224-33; PMID:19439346; http://dx.doi.org/10.1016/j.humpath.2008.12.022
62. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharmaceut Design 2007; 13:333-46; PMID:17313364; http://dx.doi.org/10.2174/138161207779313551
63. Shin S-Y, Rath O, Zebisch A, Choo S-M, Kolch W, Cho K-H. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res 2010; 70(17):6715-24; PMID:20736375; http://dx.doi.org/10.1158/0008-5472.CAN-10-1377
64. Gibson GR, Qian D, Ku JK, Lai LL. Metaplastic breast cancer: clinical features and outcomes. Am Surg 2005; 71:725-30; PMID:16468506
65. Servant N, Gravier E, Gestraud P, Laurent C, Paccard C, Biton A, Brito I, Mandel J, Asselain B, Barillot E et al. EMA - A R package for Easy Microarray data analysis. BMC Res Notes 2010; 3(1):277; PMID:21047405; http://dx.doi.org/10.1186/1756-0500-3-277
66. Barbosa-Morais NL, Dunning MJ, Samarajiwa S A, Darot JF, Ritchie ME, Lynch AG, Tavaré S. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 2010; 38(3):e17; PMID:19923232; http://dx.doi.org/10.1093/nar/gkp942
67. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M et al. STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009; 37(Database issue):D412-D416; PMID:18940858; http://dx.doi.org/10.1093/nar/gkn760
68. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-607; PMID:22460905; http://dx.doi.org/10.1038/nature11003
69. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J et al. Europe PMC Funders Group Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483(7391):570-5; PMID:22460902; http://dx.doi.org/10.1038/nature11005